On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10-15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00204-020-02912-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CYP-associated drug-drug interactions: A mission accomplished?
Arch Toxicol
November 2020
Research Unit of Biomedicine, Pharmacology and Toxicology, University of Oulu, Aapistie 5 B (POB5000), N90014, Oulu, Finland.
On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10-15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.
View Article and Find Full Text PDFEvacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.
Pharmacol Res Perspect
October 2015
Departments of Clinical Pharmacology, Drug Disposition, Medical, and Statistics, Lilly Research Laboratories, Eli Lilly and Company Indianapolis, Indiana.
Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug-drug interactions (DDI) may help guide prescribing recommendations. In vitro, evacetrapib metabolism was investigated with a panel of human recombinant cytochromes P450 (CYP).
View Article and Find Full Text PDFTobacco smoking effect on HIV-1 pathogenesis: role of cytochrome P450 isozymes.
Expert Opin Drug Metab Toxicol
November 2013
University of Missouri Kansas City, School of Pharmacy, Division of Pharmacology & Toxicology , Kansas City, MO 64108 , USA.
Introduction: Tobacco smoking is highly prevalent among the HIV-1-infected population. In addition to diminished immune response, smoking has been shown to increase HIV-1 replication and decrease response to antiretroviral therapy, perhaps through drug-drug interaction. However, the mechanism by which tobacco/nicotine increases HIV-1 replication and mediates drug-drug interaction is poorly understood.
View Article and Find Full Text PDFINDI: a computational framework for inferring drug interactions and their associated recommendations.
Mol Syst Biol
July 2012
The Blavatnik School of Computer Science, Tel-Aviv University, Tel-Aviv, Israel.
Inferring drug-drug interactions (DDIs) is an essential step in drug development and drug administration. Most computational inference methods focus on modeling drug pharmacokinetics, aiming at interactions that result from a common metabolizing enzyme (CYP). Here, we introduce a novel prediction method, INDI (INferring Drug Interactions), allowing the inference of both pharmacokinetic, CYP-related DDIs (along with their associated CYPs) and pharmacodynamic, non-CYP associated ones.
View Article and Find Full Text PDFEnzyme kinetics for clinically relevant CYP inhibition.
Curr Drug Metab
June 2005
Drug Disposition, Eisai Research Institute, Andover, MA 01810, USA.
In vitro cytochrome P450 (CYP)-associated metabolic studies have been considered cost-effective for predicting the potential clinical drug-drug interactions (DDIs), one of the major attritions in drug development. The breakthroughs during the past decade in understanding the biochemistry of CYP-mediated biotransformation and molecular biology of CYP gene regulation in humans have provided the scientific bases for such endeavors in early drug development. In this review, the enzyme kinetics of CYP inhibitions is described, with the primary focus on the ones proven with clinical relevance, namely the competitive inhibition and mechanism-based inactivation (MBI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!